Genitourinary/Renal

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AstraZeneca) D081DC00007 / PROFOUNDA Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound, D081DC00007)Hotte, Dr Sebastien OpenNCT02987543
(BMS) CA018005 / FRACTION-RCCA Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in
Participants with Advanced Renal Cell Carcinoma
Hotte, Dr Sebastien OpenNCT02996110
(BMS) CA2099KD / CheckMate 9KDA Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or
Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD:
CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD)
Hotte, Dr Sebastien OpenNCT03338790
(CCTG) IND.232A Phase II Study of Durvalumab With or Without Tremelimumab in Patients With Metastatic castration Resistant Prostate CancerHotte, Dr Sebastien OpenNCT02788773
(CCTG) IND.234 / PC-BETS - Master ProtocolProstate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening ProtocolMukherjee, Dr SomOpenNCT03385655
(CCTG) IND.234 / PC-BETS - Sub-Study AA Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpenNCT03385655 A
(CCTG) IND.234 / PC-BETS - Sub-Study BA Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpenNCT03385655 B
(CCTG) IND.234 / PC-BETS - Sub-Study CA Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234Mukherjee, Dr SomOpenNCT03385655 C
(CCTG) IND.234 / PC-BETS - Sub-Study IND.223A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpenNCT02905318
(Clovis) CO-338-052 / TRITON2A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination DeficiencyHotte, Dr Sebastien OpenNCT02952534
(JCC) Prostate HBINon-Targeted Low Dose Radiotherapy For Recurrent Prostate CancerDayes, Dr IanOpenNCT03196778
(JGH) PCS IX / PCS 9The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: An Adaptive Phase II/III Randomized Trial.Tsakiridis, Dr TheosOpenNCT02685397
(Roche) CO39303A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER Mukherjee, Dr SomOpenNCT03072238
OCOG-2013-PETMUSEImpact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder StagingMukherjee, Dr SomOpenNCT02462239
OCOG-2016-MISTERAssessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate CancerHotte, Dr Sebastien OpenNCT02813226
(Agensys) AGS-16C3F-15-3A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaHotte, Dr Sebastien On holdNCT02639182
(AstraZeneca) D933IC00003 / BAYOUA Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Cisplatin-Ineligible Patients With Unresectable Stage IV Urothelial CancerMukherjee, Dr SomOn holdNCT03459846
(UHN) TOPCOPTOward Personalizing Care for Older men with mCRPC - understanding and predicting treatment toxicities (the TOPCOP study)Hotte, Dr Sebastien On holdNCT02512185
Download PDF